75% of Medicare Seniors Face Higher Drug Premiums as Trump Ends Subsidies

For investors, government spending is never just a budget issue — it shapes corporate profits, consumer spending, and entire industries. Healthcare is one of the clearest examples. A single policy change can redirect billions of dollars between taxpayers, insurers, drugmakers, and beneficiaries. 

That’s exactly what’s happening with Medicare Part D. The Trump administration has decided to end a temporary subsidy program that helped hold prescription drug plan premiums in check, shifting more of those costs back to the market beginning in 2027. The decision may trim federal spending, but millions of Medicare beneficiaries are about to notice the change in their monthly bills.

Ending a $3.6 Billion Insurance Company Subsidy

The Centers for Medicare & Medicaid Services (CMS) confirmed on July 28 that it will allow the Medicare Part D Premium Stabilization Demonstration to expire after the 2026 plan year. The decision, first reported by The Wall Street Journal, ends a temporary Biden-era program that will provide about $3.6 billion to private insurers in 2026 to help offset higher costs created by the redesigned Medicare Part D benefit under the Inflation Reduction Act.

The demonstration program achieved its primary goal. According to CMS, it helped keep average standalone Medicare Part D premiums around $36 per month in 2026 for roughly 25 million beneficiaries.

The Trump administration argues that mission has been accomplished. After several years operating under the redesigned Part D benefit, insurers now have enough claims data to price plans without extra taxpayer support. CMS Administrator Dr. Mehmet Oz described the program as a temporary bailout for insurers that distorted pricing rather than allowing the market to determine premiums..

^{Sources: Centers for Medicare & Medicaid Services, The Wall Street Journal.}

Higher Premiums Are Coming — But Not Equally

The headline number sounds alarming, yet the details matter. CMS estimates that approximately 25% of beneficiaries will see premiums stay flat or even decline in 2027. About 30% are expected to pay less than $10 more per month. The remaining beneficiaries — roughly 45% of enrollees — could face increases ranging from $11 to $20 per month, depending on their plan and market.

That means roughly three out of every four Medicare Part D participants are expected to pay more than they do today, although the size of those increases varies considerably.

Granted, those increases are smaller than many feared. The Inflation Reduction Act still limits annual increases in the base beneficiary premium to 6% through 2029, and CMS says low-cost plan options will remain available in most markets.

Still, timing matters. Beneficiaries will receive their 2027 premium notices this fall, just as campaigning for the 2026 midterm elections intensifies.

Why Investors Should Pay Attention

For investors, this story extends well beyond Medicare premiums. The Trump administration has pursued multiple initiatives aimed at lowering prescription drug costs, including expanding Most Favored Nation pricing concepts and continuing Medicare drug price negotiations established under prior law. Ending the premium stabilization program moves in the opposite direction for consumers by asking beneficiaries to absorb more of the actual insurance cost while reducing federal support for insurers.

Ironically, that creates a different set of winners and losers. Federal spending declines by billions of dollars, private insurers lose a subsidy that supported profitability, and beneficiaries shoulder more of the premium burden. Drug manufacturers remain largely unaffected by this specific policy because the redesigned Part D benefit and negotiated drug pricing continue separately.

For investors evaluating healthcare insurers, the upcoming 2027 enrollment season will provide valuable insight into how aggressively companies price plans without federal assistance.

Key Takeaway

In short, this is less about a sudden spike in Medicare costs than a shift in who pays the bill. The Biden administration used a $3.6 billion demonstration program to cushion premium increases while insurers adjusted to the Inflation Reduction Act’s redesigned Part D benefit. The Trump administration believes that transition period has ended and taxpayers should no longer subsidize insurers.

Regardless of where investors stand on the policy, the numbers suggest most Medicare Part D beneficiaries will pay more in 2027, even if many increases remain below $10 per month. For healthcare investors, the more important question is whether insurers can retain members and protect margins once the federal safety net disappears. That answer will become much clearer when 2027 plan pricing is released this fall.

Contact [email protected] for any questions or corrections.